194 related articles for article (PubMed ID: 27146156)
1. Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.
Garona J; Pifano M; Pastrian MB; Gomez DE; Ripoll GV; Alonso DF
Clin Exp Metastasis; 2016 Aug; 33(6):589-600. PubMed ID: 27146156
[TBL] [Abstract][Full Text] [Related]
2. The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models.
Garona J; Pifano M; Orlando UD; Pastrian MB; Iannucci NB; Ortega HH; Podesta EJ; Gomez DE; Ripoll GV; Alonso DF
Int J Oncol; 2015; 46(6):2335-45. PubMed ID: 25846632
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer.
Garona J; Sobol NT; Pifano M; Segatori VI; Gomez DE; Ripoll GV; Alonso DF
Cancer Res Treat; 2019 Apr; 51(2):438-450. PubMed ID: 29879760
[TBL] [Abstract][Full Text] [Related]
4. Development and therapeutic potential of vasopressin synthetic analog [V
Garona J; Pifano M; Ripoll G; Alonso DF
Vitam Horm; 2020; 113():259-289. PubMed ID: 32138951
[TBL] [Abstract][Full Text] [Related]
5. Vasopressin Analog [V
Sobol NT; Solerno LM; Llavona C; Alonso DF; Garona J
World J Oncol; 2023 Dec; 14(6):540-550. PubMed ID: 38022396
[TBL] [Abstract][Full Text] [Related]
6. Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model.
Ripoll GV; Garona J; Pifano M; Farina HG; Gomez DE; Alonso DF
Breast Cancer Res Treat; 2013 Nov; 142(1):9-18. PubMed ID: 24122393
[TBL] [Abstract][Full Text] [Related]
7. Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice.
Garona J; Pifano M; Scursoni AM; Gomez DE; Alonso DF; Ripoll GV
Anticancer Res; 2014 Sep; 34(9):4761-5. PubMed ID: 25202055
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells.
Iannucci NB; Ripoll GV; Garona J; Cascone O; Ciccia GN; Gomez DE; Alonso DF
Future Med Chem; 2011 Dec; 3(16):1987-93. PubMed ID: 22098349
[TBL] [Abstract][Full Text] [Related]
9. Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells.
Pifano M; Garona J; Capobianco CS; Gonzalez N; Alonso DF; Ripoll GV
Front Oncol; 2017; 7():11. PubMed ID: 28194370
[TBL] [Abstract][Full Text] [Related]
10. Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer.
Ripoll GV; Garona J; Hermo GA; Gomez DE; Alonso DF
Anticancer Res; 2010 Dec; 30(12):5049-54. PubMed ID: 21187489
[TBL] [Abstract][Full Text] [Related]
11. Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation.
Giron S; Tejera AM; Ripoll GV; Gomez DE; Alonso DF
J Surg Oncol; 2002 Sep; 81(1):38-44. PubMed ID: 12210026
[TBL] [Abstract][Full Text] [Related]
12. Antimetastatic effect of desmopressin in a mouse mammary tumor model.
Alonso DF; Skilton G; Farías EF; Bal de Kier Joffé E; Gomez DE
Breast Cancer Res Treat; 1999 Oct; 57(3):271-5. PubMed ID: 10617303
[TBL] [Abstract][Full Text] [Related]
13. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer.
Ripoll GV; Giron S; Krzymuski MJ; Hermo GA; Gomez DE; Alonso DF
Anticancer Res; 2008; 28(5A):2607-11. PubMed ID: 19035285
[TBL] [Abstract][Full Text] [Related]
15. Desmopressin reduces melanoma lung metastasis in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1.
Ripoll GV; Farina HG; Yoshiji H; Gomez DE; Alonso DF
In Vivo; 2006; 20(6B):881-5. PubMed ID: 17203783
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.
Kaufmann JE; Oksche A; Wollheim CB; Günther G; Rosenthal W; Vischer UM
J Clin Invest; 2000 Jul; 106(1):107-16. PubMed ID: 10880054
[TBL] [Abstract][Full Text] [Related]
17. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells.
Pastrian MB; Guzmán F; Garona J; Pifano M; Ripoll GV; Cascone O; Ciccia GN; Albericio F; Gómez DE; Alonso DF; Iannucci NB
Mol Med Rep; 2014 Jun; 9(6):2568-72. PubMed ID: 24737067
[TBL] [Abstract][Full Text] [Related]
19. Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches.
Pifano M; Garona J; Sobol NT; Albertó M; Alonso DF; Ripoll GV
Future Med Chem; 2018 Apr; 10(8):879-894. PubMed ID: 29589487
[TBL] [Abstract][Full Text] [Related]
20. Specific chemotherapeutic agents induce metastatic behaviour through stromal- and tumour-derived cytokine and angiogenic factor signalling.
Liu G; Chen Y; Qi F; Jia L; Lu XA; He T; Fu Y; Li L; Luo Y
J Pathol; 2015 Oct; 237(2):190-202. PubMed ID: 25988668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
